BIOEMTECH and LabLogic are pleased to announce a new strategic partnership focused on expanding sales and support for BIOEMTECH’s innovative preclinical imaging solutions throughout North America.
Under the collaboration, LabLogic will provide dedicated sales and service support for BIOEMTECH’s portfolio of preclinical imaging systems to ensure comprehensive local support and responsive service. BIOEMTECH is internationally recognized for its innovative preclinical imaging technologies, including the β-eye™, γ-eye™ and φ-eye™ systems, designed to accelerate radiopharmaceutical and molecular imaging research. LabLogic is a global leader in instrumentation, software, and support in radiopharmaceutical production and research environments. With decades of experience supporting the nuclear medicine and molecular imaging community, LabLogic brings extensive expertise in quality control instrumentation, software integration and customer support.
Through this partnership, the two companies aim to strengthen access to next-generation preclinical imaging technologies, especially for novel radioligand therapeutics such as ²²⁵Ac and ²¹²Pb. By enabling experiments under clinically translational activity levels and scanning times, the technology offers a unique capability that, to the best of our knowledge, is not currently matched by other preclinical imaging systems.
“We are excited to partner with LabLogic to expand the reach and support infrastructure for BIOEMTECH imaging systems in North America”, said BIOEMTECH’s CVO, George Loudos. “LabLogic’s deep expertise in nuclear medicine and commitment to customer success make them an ideal partner for supporting our growing user community”.
“BIOEMTECH has developed an impressive portfolio of innovative preclinical imaging technologies that align strongly with the evolving needs of the radiopharmaceutical research community”, said LabLogic’s EVP, Victor Tchiprout. “We are excited to collaborate with BIOEMTECH and help researchers access advanced imaging solutions backed by reliable local service and support”.
Together, BIOEMTECH and LabLogic are committed to helping the nuclear medicine and molecular imaging community advance research, accelerate innovation, and improve access to the latest technologies supporting radiopharmaceutical development and translational science.